CN1464789A - 抗流感病毒疫苗及所述病毒疫苗的制备方法 - Google Patents
抗流感病毒疫苗及所述病毒疫苗的制备方法 Download PDFInfo
- Publication number
- CN1464789A CN1464789A CN01814944A CN01814944A CN1464789A CN 1464789 A CN1464789 A CN 1464789A CN 01814944 A CN01814944 A CN 01814944A CN 01814944 A CN01814944 A CN 01814944A CN 1464789 A CN1464789 A CN 1464789A
- Authority
- CN
- China
- Prior art keywords
- vaccine
- influenza virus
- heterochain
- antigen
- polyamine derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 113
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract description 77
- 241000700605 Viruses Species 0.000 title description 8
- 238000004519 manufacturing process Methods 0.000 title description 8
- 239000000427 antigen Substances 0.000 claims abstract description 87
- 102000036639 antigens Human genes 0.000 claims abstract description 87
- 108091007433 antigens Proteins 0.000 claims abstract description 87
- 238000000034 method Methods 0.000 claims abstract description 51
- 229920000768 polyamine Polymers 0.000 claims abstract description 45
- 238000006243 chemical reaction Methods 0.000 claims abstract description 26
- 229920001577 copolymer Polymers 0.000 claims description 34
- 229940124873 Influenza virus vaccine Drugs 0.000 claims description 27
- 101710154606 Hemagglutinin Proteins 0.000 claims description 23
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 23
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 23
- 101710176177 Protein A56 Proteins 0.000 claims description 23
- 239000000185 hemagglutinin Substances 0.000 claims description 23
- 102000005348 Neuraminidase Human genes 0.000 claims description 19
- 108010006232 Neuraminidase Proteins 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 15
- 239000005977 Ethylene Substances 0.000 claims description 13
- 230000008878 coupling Effects 0.000 claims description 11
- 238000010168 coupling process Methods 0.000 claims description 11
- 238000005859 coupling reaction Methods 0.000 claims description 11
- 102000018697 Membrane Proteins Human genes 0.000 claims description 10
- 108010052285 Membrane Proteins Proteins 0.000 claims description 10
- 238000010668 complexation reaction Methods 0.000 claims description 10
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 claims description 9
- 230000003068 static effect Effects 0.000 claims description 6
- 150000001540 azides Chemical class 0.000 claims description 5
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- RYHBGVSBFUOHAE-UHFFFAOYSA-N piperazin-1-ium;bromide Chemical compound Br.C1CNCCN1 RYHBGVSBFUOHAE-UHFFFAOYSA-N 0.000 claims description 5
- -1 piperidines bromide Chemical class 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- CUCJJMLDIUSNPU-UHFFFAOYSA-N 1-oxidopiperidin-1-ium Chemical compound [O-][NH+]1CCCCC1 CUCJJMLDIUSNPU-UHFFFAOYSA-N 0.000 claims description 3
- WTFMFQXWKFXYKA-UHFFFAOYSA-N 4-oxido-1-aza-4-azoniabicyclo[2.2.2]octane Chemical compound C1CN2CC[N+]1([O-])CC2 WTFMFQXWKFXYKA-UHFFFAOYSA-N 0.000 claims description 3
- 108010061100 Nucleoproteins Proteins 0.000 claims description 3
- 102000011931 Nucleoproteins Human genes 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- KDKGWGUUUVROTO-UHFFFAOYSA-N 1-hydroxypiperazine Chemical compound ON1CCNCC1 KDKGWGUUUVROTO-UHFFFAOYSA-N 0.000 claims description 2
- 108700010900 influenza virus proteins Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 20
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 40
- 238000011081 inoculation Methods 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 230000036039 immunity Effects 0.000 description 14
- 230000005847 immunogenicity Effects 0.000 description 14
- 206010022000 influenza Diseases 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 230000002349 favourable effect Effects 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229960003971 influenza vaccine Drugs 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000035931 haemagglutination Effects 0.000 description 5
- 230000006054 immunological memory Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 229940031626 subunit vaccine Drugs 0.000 description 5
- 210000002845 virion Anatomy 0.000 description 5
- 101710194807 Protective antigen Proteins 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000009010 Bradford assay Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002189 fluorescence spectrum Methods 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical group OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101710175243 Major antigen Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000010538 cationic polymerization reaction Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000009399 inbreeding Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920005617 polyoxidonium Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000790 scattering method Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
制剂 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 |
HAIR滴度 | 640 | 160-320 | 80 | 2560 | 20-40 | 640 | 1250 | 40 | 2560 | 160-320 | 20 | 1280 | 小于10 |
制剂 | 免疫记忆因子 | 特异性刺激因子 |
1 | 65 | 80 |
2 | 40 | 35 |
4 | 70 | 100 |
6 | 45 | 50 |
7 | 60 | 70 |
9 | 70 | 95 |
10 | 30 | 40 |
12 | 35 | 30 |
制剂 | 接种后1个月的HAIR滴度 | 免疫接种有效性(产生保护性抗体滴度的个体%) |
1 | 80-1280 | 95 |
2 | 80-320 | 91 |
4 | 160-1280 | 100 |
6 | 160-640 | 97 |
生理溶液 | 小于10 | -- |
制剂 | 病毒中和滴度 |
1 | 1∶400 |
2 | 1∶80 |
4 | 1∶400 |
6 | 1∶160 |
7 | 1∶160 |
9 | 1∶400 |
10 | 1∶160 |
12 | 1∶320 |
13 | 1∶10 |
Claims (21)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2000120902 | 2000-08-09 | ||
RU2000120902/14A RU2164148C1 (ru) | 2000-08-09 | 2000-08-09 | Вакцина против вируса гриппа и способ ее получения |
PCT/RU2001/000229 WO2002011758A1 (fr) | 2000-08-09 | 2001-06-13 | Vaccin contre le virus de la grippe et procede de fabrication correspondant |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1464789A true CN1464789A (zh) | 2003-12-31 |
CN1464789B CN1464789B (zh) | 2010-12-01 |
Family
ID=20238868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN018149448A Expired - Fee Related CN1464789B (zh) | 2000-08-09 | 2001-06-13 | 抗流感病毒疫苗及所述病毒疫苗的制备方法 |
Country Status (5)
Country | Link |
---|---|
KR (1) | KR100568013B1 (zh) |
CN (1) | CN1464789B (zh) |
AU (2) | AU2001269640B2 (zh) |
RU (1) | RU2164148C1 (zh) |
WO (1) | WO2002011758A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102858348A (zh) * | 2010-06-24 | 2013-01-02 | Npo佩特洛瓦克斯制药有限责任公司 | 杂链脂族聚-n-氧化物共聚物及基于其的疫苗接种剂和药物 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2446824C2 (ru) * | 2010-07-20 | 2012-04-10 | Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения и социального развития Российской Федерации | Вакцина против гриппа и способ ее получения |
NZ622731A (en) * | 2011-09-30 | 2016-04-29 | Medicago Inc | Increasing virus-like particle yield in plants |
RU2740751C1 (ru) * | 2019-08-28 | 2021-01-20 | Общество с ограниченной ответственностью "Развитие БиоТехнологий" | Способ получения тетравалентной субъединичной противогриппозной вакцины |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1580617A1 (ru) * | 1988-05-13 | 1997-02-10 | Институт иммунологии | Способ получения вакцины против вируса гриппа |
RU2073031C1 (ru) * | 1990-08-06 | 1997-02-10 | Некрасов Аркадий Васильевич | Производные поли-1,4-этиленпиперазина, обладающие иммуномодулирующей, противовирусной и антибактериальной активностями |
RU2112542C1 (ru) * | 1997-02-28 | 1998-06-10 | Аркадий Васильевич Некрасов | Препарат для лечения патологических состояний соединительной ткани |
RU2153354C1 (ru) * | 1999-03-31 | 2000-07-27 | Московский городской научно-практический центр борьбы с туберкулезом | Вакцина против туберкулеза |
-
2000
- 2000-08-09 RU RU2000120902/14A patent/RU2164148C1/ru active
-
2001
- 2001-06-13 WO PCT/RU2001/000229 patent/WO2002011758A1/ru active IP Right Grant
- 2001-06-13 AU AU2001269640A patent/AU2001269640B2/en not_active Ceased
- 2001-06-13 KR KR1020037001870A patent/KR100568013B1/ko not_active IP Right Cessation
- 2001-06-13 AU AU6964001A patent/AU6964001A/xx active Pending
- 2001-06-13 CN CN018149448A patent/CN1464789B/zh not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102858348A (zh) * | 2010-06-24 | 2013-01-02 | Npo佩特洛瓦克斯制药有限责任公司 | 杂链脂族聚-n-氧化物共聚物及基于其的疫苗接种剂和药物 |
Also Published As
Publication number | Publication date |
---|---|
RU2164148C1 (ru) | 2001-03-20 |
WO2002011758A1 (fr) | 2002-02-14 |
AU6964001A (en) | 2002-02-18 |
KR100568013B1 (ko) | 2006-04-05 |
KR20030059096A (ko) | 2003-07-07 |
AU2001269640B2 (en) | 2005-12-22 |
WO2002011758A8 (fr) | 2003-07-24 |
CN1464789B (zh) | 2010-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2008293504B2 (en) | Immunogenic compositions and methods | |
CN108329379B (zh) | H7亚型流感病毒h7n9的普通型/嵌合型病毒样颗粒及制备方法、应用和疫苗 | |
CN1073878A (zh) | 用病毒抗原表达特异性免疫原 | |
CN1091978A (zh) | 粒细胞-巨噬细胞-集落刺激因子作为疫苗佐剂的用途 | |
RU2009144125A (ru) | Виросомы, содержащие гемагглютинин, полученный из вируса гриппа, вырабатываемого в клеточной линии; композиции, методы получения и применение на их основе | |
AU2016282761B2 (en) | Inactivated canine influenza vaccines and methods of making and uses thereof | |
CN101489589A (zh) | 免疫原性组合物 | |
US11389523B2 (en) | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein | |
TWI781700B (zh) | 固定化病毒粒子的製造方法及疫苗的製造方法 | |
CN1049523A (zh) | 大肠杆菌疫苗 | |
CN1464789A (zh) | 抗流感病毒疫苗及所述病毒疫苗的制备方法 | |
US20120107354A1 (en) | Viral vaccine and process for preparing the same | |
CN108567978B (zh) | 碳量子点佐剂及含碳量子点佐剂的疫苗 | |
Abd El-Aziz et al. | Evaluation of cell-mediated immunity of E. coli nanovaccines in chickens | |
KR20120131725A (ko) | 고병원성 조류인플루엔자 a h5n1 바이러스 유사입자 및 이를 이용한 가금용 백신 | |
KR102529010B1 (ko) | 조작된 인플루엔자 헤마글루티닌 폴리펩티드의 변형 | |
KR20170030635A (ko) | 바이러스 유사 입자를 포함하는 백신 | |
EP2195020A1 (en) | Inactivated influenza vaccine | |
Rehmani et al. | The influence of adjuvants on oral vaccination of chickens against Newcastle disease | |
CN1477972A (zh) | 获得抗原性聚集物的方法及其在制剂中的用途 | |
CN101049508A (zh) | 携带结核分支杆菌Ag85B的减毒伤寒杆菌载体疫苗 | |
CN1101289A (zh) | 活的复合疫苗 | |
CN1616654A (zh) | 一种sars病毒的灭活及纯化方法以及制备含有所述灭活病毒疫苗的方法及所述疫苗 | |
CN111450246B (zh) | 一种三价流感病毒亚单位疫苗及其制备方法 | |
CN1305527C (zh) | 乙型肝炎治疗疫苗及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20081212 Address after: Russian Federation Moscow Applicant after: Obchtchestvo S. Ogranitchennoi Otvetstvennostyou Npo Petrovaks Farm Address before: Moscow, Russian Federation Applicant before: Rem Viktorovich Petrov Co-applicant before: Khaitov Rakhim Musaevich Co-applicant before: Nekrasov Arkadij Vasil Evich Co-applicant before: Natalia Grigoryevina Puchkova application |
|
ASS | Succession or assignment of patent right |
Owner name: NPO PETRO WAX PHARMACEUTICAL CO. Free format text: FORMER OWNER: R. V. PETROV;A. V. NEKRASOV;A. S. IVANOVA Effective date: 20081212 |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101201 Termination date: 20180613 |